Translational Imaging for Accelerated Drug Development
Delivering unrivalled translational imaging capabilities, using our portfolio of imaging platforms, infrastructure and expertise
Monitoring, assessing, and characterising novel therapeutics in pre-clinical models plays an essential part in drug development.
All drugs have an optimum concentration range in which maximum benefit is achieved. Translational imaging can help scientists optimise the selective delivery of a therapeutic concentration of a drug to its target tissue.
Who is MDC?
We are an independent, not-for-profit organisation and part of the Catapult Network established by Innovate UK. Our vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. We support drug discovery innovators by making world-class expertise, facilities, complex technologies
As an expert in medicines discovery, Medicines Discovery Catapult (MDC) has established a portfolio of advanced imaging platforms, infrastructure and expertise, to support the assessment of novel therapeutics in pre-clinical models, to accelerate drug development and achieve maximum therapeutic benefit.
and advanced analytics accessible. We connect the life sciences ecosystem, driving a global focus on barriers to innovation in areas of unmet patient and technological need. We enable successful medicines discovery by industrialising new technologies to drive the adoption of new scientific tools and techniques.
As an SME, working with MDC allows us access to scientific know-how and in vivo imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerates our ability to develop product. MDC perform an absolutely vital role in supporting us getting our novel treatments to clinical trials.
Gareth Wakefield Chief Technology Officer, Xerion HealthcareThe ability to perform non-invasive imaging to assess and study novel therapeutics requires significant investment in infrastructure as well as highly experienced specialists, and access to relevant disease models. At MDC, we provide access to all three.
